Reducing risk of Type 2 diabetes

Tirzepatide may effectively reduce the risk of developing Type 2 diabetes in adults who are overweight or have prediabetes following three years of weekly injections.

In a study involving more than 1,000 patients, those who received weekly injections of tirzepatide reduced their risk of progressing to Type 2 diabetes by 94% compared with those who received placebo, according to trial data presented in an Eli Lilly press release and reported on by CNN. The patients who discontinued treatment regained their weight and showed an increase in the progression of Type 2 diabetes.

The findings, which will be submitted to a peer-reviewed journal, underscored the long-term benefits of tirzepatide. However, it remains uncertain whether data from the study will be sufficient to support an application for the prevention of diabetes.

Read more: CNN

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.